SCHEMBL17479705

SCHEMBL17479705

NCCCN(C1CCCCC1)S(=O)(=O)c1cccc(-c2nc3ccccc3o2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 6/20 0.42
▸ TSHR P16473 3/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ KDM4E B2RXH2 6/20 0.40
▸ HPGD P15428 5/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ KMT2A Q03164 5/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ PKM P14618 1/20 0.39
▸ PTPN2 P17706 5/20 0.38
▸ PTPN1 P18031 5/20 0.38
▸ PTPN5 P54829 5/20 0.38
▸ HSPD1 P10809 4/20 0.38
▸ HSPE1 P61604 4/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ MAPT P10636 4/20 0.38
▸ GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17479006 0.89 SMN1; SMN2 (0.43) HSD17B10TSHRMAPK1KDM4EHPGD
SCHEMBL17479697 0.88 MAPK1 (0.38) HSD17B10TSHRMAPK1KDM4EHPGD
SCHEMBL17479172 0.87 SMN1; SMN2 (0.42) HSD17B10TSHRMAPK1KDM4EHPGD
SCHEMBL17479324 0.86 TSHR (0.38) HSD17B10TSHRMAPK1KDM4EHPGD
SCHEMBL17479726 0.86 TSHR (0.41) HSD17B10TSHRMAPK1SMN1; SMN2ALDH1A1
SCHEMBL17479698 0.84 SMN1; SMN2 (0.44) HSD17B10TSHRMAPK1KDM4EHPGD
SCHEMBL17479797 0.81 MEN1 (0.53) HSD17B10TSHRKDM4EHPGDSMN1; SMN2
SCHEMBL17479795 0.80 SMN1; SMN2 (0.45) HSD17B10TSHRMAPK1KDM4EHPGD
SCHEMBL17479791 0.80 KDM4E (0.42) HSD17B10MAPK1KDM4EHPGDSMN1; SMN2
SCHEMBL17479756 0.80 MAPT (0.51) HSD17B10TSHRMAPK1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP claimed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US claimed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US claimed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP claimed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO claimed
CN-107001283-B FLT3 receptor antagonists 国家健康与医学研究院 2021-05-25 — — CN disclosed
US-20200171022-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-06-04 — — US disclosed
CN-111093640-A FLT3 inhibitors for improving opioid pain therapy 国家健康与医学研究院 2020-05-01 — — CN disclosed
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP disclosed
EP-3624780-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-03-25 — — EP disclosed
WO-2018211018-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-11-22 — — WO disclosed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US disclosed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US disclosed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP disclosed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS FLT3, CSF1R, CSF3R HSD17B10 4204/4885TSHR 69/4885MAPK1 1387/4885
US-10065937-B2 FLT3 receptor antagonists FLT3, CSF1R, CSF3R HSD17B10 4204/4885TSHR 69/4885MAPK1 1387/4885
US-20200171022-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS FLT3, CSF1R, OPRL1 HSD17B10 4833/4885TSHR 2361/4885MAPK1 601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback